284 related articles for article (PubMed ID: 32433005)
1. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.
Qiu J; Tang W; Du C
Curr Cancer Drug Targets; 2020; 20(9):720-727. PubMed ID: 32433005
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
Front Immunol; 2021; 12():653437. PubMed ID: 34349755
[TBL] [Abstract][Full Text] [Related]
3. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma.
Friend BD; Venick RS; McDiarmid SV; Zhou X; Naini B; Wang H; Farmer DG; Busuttil RW; Federman N
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643391
[TBL] [Abstract][Full Text] [Related]
4. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period.
Chen GH; Wang GB; Huang F; Qin R; Yu XJ; Wu RL; Hou LJ; Ye ZH; Zhang XH; Zhao HC
Transpl Immunol; 2021 Jun; 66():101386. PubMed ID: 33744409
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation.
Zou WL; Zang YJ; Chen XG; Shen ZY
Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):145-51. PubMed ID: 18397848
[TBL] [Abstract][Full Text] [Related]
6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature.
Zhang P; Zhu G; Li L; Lai G; Wang Z; Sun C; Xia W; Wu L
Transplant Rev (Orlando); 2022 Dec; 36(4):100712. PubMed ID: 35870411
[TBL] [Abstract][Full Text] [Related]
8. Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma.
Kang E; Martinez M; Moisander-Joyce H; Saenger YM; Griesemer AD; Kato T; Yamashiro DJ; Remotti H; Gartrell RD
Pediatr Transplant; 2022 May; 26(3):e14209. PubMed ID: 34907641
[TBL] [Abstract][Full Text] [Related]
9. Pediatric liver transplantation for hepatocellular cancer and rare liver malignancies: US multicenter and single-center experience (1981-2015).
Vinayak R; Cruz RJ; Ranganathan S; Mohanka R; Mazariegos G; Soltys K; Bond G; Tadros S; Humar A; Marsh JW; Selby RR; Reyes J; Sun Q; Haberman K; Sindhi R
Liver Transpl; 2017 Dec; 23(12):1577-1588. PubMed ID: 28834194
[TBL] [Abstract][Full Text] [Related]
10. Treatment of recurrent hepatocellular carcinoma after liver transplantation.
Kim HR; Cheon SH; Rha SY; Lee S; Han KH; Chon CY; Lee JD; Sung JS; Chung HC
Asia Pac J Clin Oncol; 2011 Sep; 7(3):258-69. PubMed ID: 21884437
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
Cholongitas E; Mamou C; Rodríguez-Castro KI; Burra P
Transpl Int; 2014 Oct; 27(10):1039-49. PubMed ID: 24943720
[TBL] [Abstract][Full Text] [Related]
12. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
[TBL] [Abstract][Full Text] [Related]
13. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
[TBL] [Abstract][Full Text] [Related]
14. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma.
Cheng JW; Shi YH; Fan J; Huang XW; Qiu SJ; Xiao YS; Wang Z; Dai Z; Tang ZY; Zhou J
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1445-53. PubMed ID: 21809031
[TBL] [Abstract][Full Text] [Related]
15. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
de'Angelis N; Landi F; Carra MC; Azoulay D
World J Gastroenterol; 2015 Oct; 21(39):11185-98. PubMed ID: 26494973
[TBL] [Abstract][Full Text] [Related]
16. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators.
Zimmerman MA; Ghobrial RM; Tong MJ; Hiatt JR; Cameron AM; Hong J; Busuttil RW
Arch Surg; 2008 Feb; 143(2):182-8; discussion 188. PubMed ID: 18283144
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcome of Liver Resection Versus Transplantation for Hepatocellular Carcinoma in a Region Where Living Donation is a Main Source.
Sung PS; Yang H; Na GH; Hwang S; Kang D; Jang JW; Bae SH; Choi JY; Kim DG; Yoon SK; You YK
Ann Transplant; 2017 May; 22():276-284. PubMed ID: 28473688
[TBL] [Abstract][Full Text] [Related]
18. Laparoscopic liver resection facilitates salvage liver transplantation for hepatocellular carcinoma.
Laurent A; Tayar C; Andréoletti M; Lauzet JY; Merle JC; Cherqui D
J Hepatobiliary Pancreat Surg; 2009; 16(3):310-4. PubMed ID: 19280110
[TBL] [Abstract][Full Text] [Related]
19. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?
Adam R; Azoulay D; Castaing D; Eshkenazy R; Pascal G; Hashizume K; Samuel D; Bismuth H
Ann Surg; 2003 Oct; 238(4):508-18; discussion 518-9. PubMed ID: 14530722
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation.
Zhuang L; Mou HB; Yu LF; Zhu HK; Yang Z; Liao Q; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Feb; 19(1):91-93. PubMed ID: 31706859
[No Abstract] [Full Text] [Related]
[Next] [New Search]
